Sedana Medical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Sedana Medical wird ein jährliches Gewinn- und Umsatzwachstum von 62.8% bzw. 38.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 44.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -1.1% betragen.

Wichtige Informationen

61.1%

Wachstumsrate der Gewinne

46.5%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	27.0%
Wachstumsrate der Einnahmen	38.3%
Zukünftige Eigenkapitalrendite	-1.1%
Analystenabdeckung	Low
Zuletzt aktualisiert	02 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Sedana Medical AB (publ) Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 28

Recent updates

After Leaping 27% Sedana Medical AB (publ) (STO:SEDANA) Shares Are Not Flying Under The Radar

Jun 07

Sedana Medical AB (publ) Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 28

Here's Why We're Not Too Worried About Sedana Medical's (STO:SEDANA) Cash Burn Situation

Mar 16

Optimistic Investors Push Sedana Medical AB (publ) (STO:SEDANA) Shares Up 34% But Growth Is Lacking

Dec 21

We're Hopeful That Sedana Medical (STO:SEDANA) Will Use Its Cash Wisely

Oct 29

Sedana Medical (STO:SEDANA) Is In A Good Position To Deliver On Growth Plans

Jul 12

Analysts Just Made A Major Revision To Their Sedana Medical AB (publ) (STO:SEDANA) Revenue Forecasts

May 01

We're Hopeful That Sedana Medical (STO:SEDANA) Will Use Its Cash Wisely

Feb 17

Analysts Are More Bearish On Sedana Medical AB (publ) (STO:SEDANA) Than They Used To Be

Jan 20

Here's Why We're Not Too Worried About Sedana Medical's (STO:SEDANA) Cash Burn Situation

Oct 05

Companies Like Sedana Medical (STO:SEDANA) Are In A Position To Invest In Growth

Jul 05

Sedana Medical AB (publ) (STO:SEDANA) Analysts Just Slashed This Year's Estimates

May 03

Sedana Medical AB (publ) (STO:SEDANA) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 20

Gewinn- und Umsatzwachstumsprognosen

OM:SEDANA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	383	15	-22	12	2
12/31/2025	239	-41	-67	-12	2
12/31/2024	183	-58	-63	98	2
6/30/2024	169	-41	-176	15	N/A
3/31/2024	165	-23	-204	-23	N/A
12/31/2023	154	-60	-207	-38	N/A
9/30/2023	145	-57	-224	-69	N/A
6/30/2023	137	-58	-244	-92	N/A
3/31/2023	127	-71	-240	-95	N/A
12/31/2022	123	-74	-253	-115	N/A
9/30/2022	133	-54	-238	-94	N/A
6/30/2022	135	-62	-219	-82	N/A
3/31/2022	148	-68	-177	-55	N/A
12/31/2021	159	-58	-151	-41	N/A
9/30/2021	159	-53	-144	-37	N/A
6/30/2021	152	-51	-124	-27	N/A
3/31/2021	153	-38	-105	-13	N/A
12/31/2020	142	-27	-92	-8	N/A
9/30/2020	116	-22	-85	-14	N/A
6/30/2020	111	-14	-75	-13	N/A
3/31/2020	88	-12	-74	-16	N/A
12/31/2019	72	-16	-61	-7	N/A
9/30/2019	67	-13	-57	-12	N/A
6/30/2019	63	-11	-47	-7	N/A
3/31/2019	60	-10	-38	-3	N/A
12/31/2018	58	-7	-35	-6	N/A
9/30/2018	53	-3	-22	9	N/A
6/30/2018	51	-4	-34	-9	N/A
3/31/2018	47	-3	N/A	-3	N/A
12/31/2017	42	-4	N/A	0	N/A
9/30/2017	41	-3	N/A	-7	N/A
6/30/2017	39	0	N/A	10	N/A
3/31/2017	36	0	N/A	0	N/A
12/31/2016	34	1	N/A	0	N/A
12/31/2015	28	-1	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SEDANA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SEDANA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SEDANA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SEDANADie Einnahmen des Unternehmens (35.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.9% pro Jahr).

Hohe Wachstumseinnahmen: SEDANADie Einnahmen des Unternehmens (35.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SEDANA wird voraussichtlich in 3 Jahren unrentabel sein.

Sedana Medical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to kr0.27 loss

Price target increased by 21% to kr43.00

Consensus estimates of losses per share improve by 15%

Sedana Medical AB (publ) Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Forecast to breakeven in 2026

Consensus EPS estimates fall by 16%

Recent updates

Supply Chain & Manufacturing Director recently bought kr138k worth of stock

Consensus EPS estimates upgraded to kr0.27 loss

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 21% to kr43.00

Sedana Medical AB (publ) (OM:SEDANA) agreed to acquire Innovatif Cekal Sdn. Bhd. for SEK 35 million.

Chief Medical Officer recently sold kr206k worth of stock

After Leaping 27% Sedana Medical AB (publ) (STO:SEDANA) Shares Are Not Flying Under The Radar

Less than half of directors are independent

Sedana Medical AB (publ) Completes Patient Recruitment for its Clinical Program in the US

Consensus estimates of losses per share improve by 15%

Sedana Medical AB (publ) Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

First quarter 2024 earnings released: EPS: kr0.21 (vs kr0.16 loss in 1Q 2023)

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Ola Magnusson and Eva Walde Decline Re-Election as Board Members of Sedana Medical AB (publ)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Not Too Worried About Sedana Medical's (STO:SEDANA) Cash Burn Situation

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

Consensus EPS estimates fall by 16%

Optimistic Investors Push Sedana Medical AB (publ) (STO:SEDANA) Shares Up 34% But Growth Is Lacking

Sedana Medical AB (publ) Files Submission for Paediatric Indication

New minor risk - Share price stability

Sedana Medical Secures Data Exclusivity and Market Protection for Sedaconda (isoflurane) Until 2031

Sedana Medical AB (Publ) Announces the Main Results from the Paediatric Isocomfort Study

Consensus EPS estimates upgraded to kr0.45 loss, revenue downgraded

Sedana Medical AB (publ), Annual General Meeting, May 22, 2024

Chief Medical Officer recently bought kr900k worth of stock

We're Hopeful That Sedana Medical (STO:SEDANA) Will Use Its Cash Wisely

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sedana Medical AB (publ) Announces Completion of Enrollment

Sedana Medical AB (publ) Announces Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for Sedaconda (Isoflurane) in United Kingdom

Chief Financial Officer recently bought kr1.8m worth of stock

No longer forecast to breakeven

Consensus EPS estimates upgraded to kr0.57 loss

New minor risk - Profitability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Profitability

Price target decreased by 11% to kr64.00

Sedana Medical AB (publ) Informs About Adjusted US Submission Plan Following FDA Interaction

Sedana Medical (STO:SEDANA) Is In A Good Position To Deliver On Growth Plans

New minor risk - Share price stability

Sedana Medical AB (Publ) Announces Thomas Eklund Decline Re-Election

Analysts Just Made A Major Revision To Their Sedana Medical AB (publ) (STO:SEDANA) Revenue Forecasts

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.3% to kr70.00

We're Hopeful That Sedana Medical (STO:SEDANA) Will Use Its Cash Wisely

Sedana Medical AB (publ) Receives Market Approval for Sedaconda in Italy

Sedana Medical AB (publ) to Report Fiscal Year 2022 Final Results on Apr 03, 2023

Analysts Are More Bearish On Sedana Medical AB (publ) (STO:SEDANA) Than They Used To Be

Sedana Medical AB (publ) Completes Patient Recruitment for Pediatric IsoCOMFORT Study

Sedana Medical Receives FDA Fast Track Designation in the United States

Sedana Medical Receives Positive Opinion from Ema's Pediatric Committee on Reduced Pediatric Study Design

No longer forecast to breakeven

Consensus forecasts updated

No longer forecast to breakeven

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Sedana Medical AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Here's Why We're Not Too Worried About Sedana Medical's (STO:SEDANA) Cash Burn Situation

Consensus estimates of losses per share improve by 23%

Forecast to breakeven in 2024

Consensus revenue estimates fall by 17%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Companies Like Sedana Medical (STO:SEDANA) Are In A Position To Invest In Growth

Sedana Medical AB (publ) Approves Board Changes

Consensus revenue estimates fall by 23%

Independent Director recently bought kr161k worth of stock

Sedana Medical AB (publ) (STO:SEDANA) Analysts Just Slashed This Year's Estimates

Forecast breakeven date pushed back to 2024

Price target decreased to kr96.00